NeoPharm CO. LTD (092730) — Capital Reinvestment Ratio
Latest as of September 2025:
0.08x
NeoPharm CO. LTD (092730) has a Capital Reinvestment Ratio of 0.08x as of September 2025, meaning it reinvests 0% of its operating cash flow (₩5.88 Billion) in capital expenditures (₩446.60 Million). See NeoPharm CO. LTD (092730) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.08x
Capex / Operating Cash Flow
Operating Cash Flow
₩5.88 Billion
KRW
Capital Expenditures
₩446.60 Million
KRW
Data as of
Sep 2025
Most recent filing
NeoPharm CO. LTD Capital Reinvestment Ratio (2012–2024)
This chart tracks NeoPharm CO. LTD's Capital Reinvestment Ratio across 11 annual periods.
Annual Capital Reinvestment Ratio for NeoPharm CO. LTD (2012–2024)
Year-by-year Capital Reinvestment Ratio for NeoPharm CO. LTD from 2012 to 2024. For live market cap and broader valuation context, see NeoPharm CO. LTD stock valuation.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.17x | ₩18.63 Billion | ₩3.08 Billion | ▼ -81.6% |
| 2023 | 0.90x | ₩23.26 Billion | ₩20.83 Billion | ▲ +1916.3% |
| 2022 | 0.04x | ₩18.16 Billion | ₩806.43 Million | ▲ +200.8% |
| 2021 | 0.01x | ₩21.68 Billion | ₩320.11 Million | ▼ -11.7% |
| 2020 | 0.02x | ₩17.07 Billion | ₩285.62 Million | ▼ -94.6% |
| 2019 | 0.31x | ₩19.22 Billion | ₩5.90 Billion | ▲ +155.9% |
| 2018 | 0.12x | ₩16.18 Billion | ₩1.94 Billion | ▲ +44.4% |
| 2017 | 0.08x | ₩10.65 Billion | ₩884.71 Million | ▼ -45.8% |
| 2016 | 0.15x | ₩9.16 Billion | ₩1.40 Billion | ▲ +18.8% |
| 2015 | 0.13x | ₩6.09 Billion | ₩786.89 Million | ▼ -57.8% |
| 2012 | 0.31x | ₩564.34 Million | ₩172.47 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow